



PHARMACEUTICAL 2022











RealRate

PHARMACEUTICAL 2022

Xencor Inc Rank 14 of 475



The relative strengths and weaknesses of Xencor Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xencor Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 336% points. The greatest weakness of Xencor Inc is the variable Other Assets, reducing the Economic Capital Ratio by 9.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 242%, being 518% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	424,368
Cost of Goods Sold	0
Intangible Assets	16,493
Liabilities, Current	70,738
Liabilities, Non-Current	33,969
Other Assets	369,110
Other Compr. Net Income	-1,584
Other Expenses	0
Other Liabilities	0
Other Net Income	38,864
Property and Equipment	28,240
Research and Development	192,507
Revenues	275,111
Selling, General and Administrative Expense	38,837

Output Variable	Value in 1000 USD
Assets	838,211
Liabilities	104,707
Expenses	231,344
Stockholders Equity	733,504
Net Income	82,631
Comprehensive Net Income	81,839
Economic Capital Ratio	242%

